Xilio Therapeutics (XLO)

• Market cap: $38.9M
• 1 day: -0.83%
• 5 days: 10.53%
• 1 month: -6.89%
• 3 months: -34.07%
• 6 months: -4.86%
• Year to date: -29.76%
• 1 year: -38.89%
• 5 years: -95.30%
• 10 years: -95.30%
• Sector: Healthcare
• Industry: Biotechnology

About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Employees: 73

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

150% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]

96% more capital invested

Capital invested by funds: $12.6M [Q3] → $24.7M (+$12.1M) [Q4]

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

20.25% more ownership

Funds ownership: 36.3% [Q3] → 56.55% (+20.25%) [Q4]

6% more funds holding

Funds holding: 33 [Q3] → 35 (+2) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6